CliffBio
biologic

Stelara

ustekinumab

Loss of exclusivitySeptember 2021projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameStelara
Active ingredientustekinumab
Strength45MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2009
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Stelara patent cliff — loss of exclusivity September 2021 | CliffBio